Form 8-K - Current report:
SEC Accession No. 0001558370-24-012519
Filing Date
2024-08-28
Accepted
2024-08-28 17:01:32
Documents
16
Period of Report
2024-08-28
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K pahc-20240828x8k.htm   iXBRL 8-K 32009
2 EX-99.1 pahc-20240828xex99d1.htm EX-99.1 718650
3 GRAPHIC pahc-20240828xex99d1001.jpg GRAPHIC 8907
  Complete submission text file 0001558370-24-012519.txt   936043

Data Files

Seq Description Document Type Size
4 EX-101.SCH pahc-20240828.xsd EX-101.SCH 3255
5 EX-101.LAB pahc-20240828_lab.xml EX-101.LAB 18712
6 EX-101.PRE pahc-20240828_pre.xml EX-101.PRE 13048
18 EXTRACTED XBRL INSTANCE DOCUMENT pahc-20240828x8k_htm.xml XML 4929
Mailing Address GLENPOINTE CENTRE EAST, 3RD FLOOR 300 FRANK W. BURR BLVD., SUITE 21 TEANECK NJ 07666
Business Address GLENPOINTE CENTRE EAST, 3RD FLOOR 300 FRANK W. BURR BLVD., SUITE 21 TEANECK NJ 07666 201-329-7300
PHIBRO ANIMAL HEALTH CORP (Filer) CIK: 0001069899 (see all company filings)

EIN.: 131840497 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-36410 | Film No.: 241256490
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)